|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The APAC Breast Cancer Therapeutics Market Report shows that in the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women. There have been wide-reaching changes in the breast cancer market over the past four decades, particularly in relation to the usage of targeted therapies, which has increased significantly. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies. The market is set to be driven by a number of new approvals for drugs and an increased uptake of premium targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.
Other Key Points in Report:
The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
-What are the competitive advantages of the existing novel drugs?
-Are these targeted therapies used to the same magnitude in all the countries assessed?
-What are the factors contributing to the uptake of these drugs in each country?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
-Which classes of novel drugs are most prominent within the pipeline?
-Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
-Which Asia-Pacific countries should expect a late launch and a lower uptake of the late-stage pipeline drugs?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170046/buying
Table of Content: An Overview
2 Introduction 9
2.1 Disease Introduction 9
2.2 Symptoms 10
2.3 Etiology 10
2.4 Pathophysiology 11
2.5 Epidemiology 12
2.6 Diagnosis and Classification 14
2.7 Prognosis and Disease Staging 16
2.8 Treatment Options 18
2.8.1 Surgery and Radiation Therapy 18
2.8.2 Chemotherapy 19
2.8.3 Hormonal Therapies 19
2.8.4 Targeted Therapies 20
2.8.5 Resistance to Pharmacological Therapies 20
2.9 Treatment Guidelines 21
3 Marketed Products 24
3.1 Overview 24
3.1.1 Herceptin (trastuzumab)-Genentech 24
3.1.2 Perjeta (pertuzumab)-Genentech 26
3.1.3 Afinitor (everolimus)-Novartis 27
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate)-Novartis 28
3.1.5 Ibrance (palbociclib)-Pfizer 29
3.1.6 Ixempra (ixabepilone)-Bristol-Myers Squibb 29
3.1.7 Halaven (eribulin mesylate)-Eisai 30
3.1.8 Avastin (bevacizumab)-Genentech 31
3.1.9 Kadcyla (ado-trastuzumab emtansine)-Genentech 31
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170046/discount
3.2 Marketed Products Heatmap 32
3.2.1 Herceptin 33
3.2.2 Perjeta 35
3.2.3 Afinitor 35
3.2.4 Tykerb/Tyverb 35
3.2.5 Ibrance 36
3.2.6 Ixempra 37
3.2.7 Halaven 37
3.3 Measuring the Effectiveness of Treatment 38
3.4 Conclusion 38
4 Pipeline Products 39
4.1 Overall Pipeline 39
4.1.1 Pipeline by Molecular Target 40
4.2 Clinical Trials 43
4.2.1 Failure Rate 43
4.2.2 Patient Enrollment and Clinical Trial Size 45
4.2.3 Duration 49
4.3 Competitive Clinical Trials Metrics Analysis 52
5 Promising Drug Candidates in Pipeline 53
5.1 Abemaciclib-Eli Lily 53
5.1.1 Abemaciclib Forecast 53
5.2 Buparlisib-Novartis 54
5.2.1 Buparlisib Forecast 55
5.3 Lynparza (olaparib)-AstraZeneca 56
5.3.1 Lynparza Forecast 56
5.4 Neratinib-Puma Biotechnology 57
5.4.1 Neratinib Forecast 58
5.5 Ribociclib-Novartis 59
5.5.1 Ribociclib Forecast 60
5.6 NeuVax (nelipepimut-S)-Galena Biopharma 60
5.7 Veliparib-AbbVie 61
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170046/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
